Skip to main content
Erschienen in: Pathology & Oncology Research 1/2018

29.03.2017 | Original Article

Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary

verfasst von: Attila Péter Király, Krisztián Kállay, Ambrus Gángó, Ádám Kellner, Miklós Egyed, Anita Szőke, Richárd Kiss, István Vályi-Nagy, Judit Csomor, András Matolcsy, Csaba Bödör

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Although genetic predisposition to haematological malignancies has long been known, genetic testing is not yet the part of the routine diagnostics. In the last ten years, next generation sequencing based studies identified novel germline mutations in the background of familial aggregation of certain haematologic disorders including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). This is supported by the fact that the myeloid neoplasms with genetic predisposition represent a new category in the revised 2016 World Health Organization classification. According to the new classification, these disorders are subdivided based on the clinical and genetic features, including myeloid neoplasms with germline predisposition alone, or with pre-existing platelet disorder, cytopaenias or other organ failures. The predisposing genetic factors include mutations in the RUNX1, CEBPA, GATA2, ANKRD26, ETV6, DDX41, TERC or TERT and SRP72 genes. The genes affected in these syndromes are important regulators of haemopoiesis and are frequently implicated in leukaemogenesis, providing deeper insight into the understanding of normal and malignant haemopoiesis. Despite the growing knowledge of germline predisposing events in the background of familial myeloid malignancies, the germline genetic component is still unknown in a subset of these pedigrees. Here, we present the first study of inherited myeloid malignancies in Hungary. We identified three families with apparent clustering of myeloid malignancies with nine affected individuals across these pedigrees. All tested individuals were negative for CEBPA, GATA2, RUNX1, ANKRD26, ETV6, DDX41, TERC or TERT and SRP72 mutations, suggesting the presence of so far unidentified predisposing mutations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Porter CC (2016) Germ line mutations associated with leukemias. Hematol Am Soc Hematol Educ Prog 2016(1):302–308 Porter CC (2016) Germ line mutations associated with leukemias. Hematol Am Soc Hematol Educ Prog 2016(1):302–308
2.
Zurück zum Zitat West AH, Godley LA, Churpek JE (2014) Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 1310:111–118CrossRefPubMedPubMedCentral West AH, Godley LA, Churpek JE (2014) Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 1310:111–118CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC et al (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 43(10):1012–1017CrossRefPubMedPubMedCentral Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC et al (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 43(10):1012–1017CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kirwan M, Walne AJ, Plagnol V, Velangi M, Ho A, Hossain U et al (2012) Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet 90(5):888–892CrossRefPubMedPubMedCentral Kirwan M, Walne AJ, Plagnol V, Velangi M, Ho A, Hossain U et al (2012) Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet 90(5):888–892CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Pippucci T, Savoia A, Perrotta S, Pujol-Moix N, Noris P, Castegnaro G et al (2011) Mutations in the 5′ UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 88(1):115–120CrossRefPubMedPubMedCentral Pippucci T, Savoia A, Perrotta S, Pujol-Moix N, Noris P, Castegnaro G et al (2011) Mutations in the 5′ UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 88(1):115–120CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N et al (2015) Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27(5):658–670CrossRefPubMed Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N et al (2015) Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27(5):658–670CrossRefPubMed
7.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMed Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMed
8.
Zurück zum Zitat Duployez N, Lejeune S, Renneville A, Preudhomme C (2016) Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Rev Hematol 9(12):1189–1202CrossRefPubMed Duployez N, Lejeune S, Renneville A, Preudhomme C (2016) Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Rev Hematol 9(12):1189–1202CrossRefPubMed
9.
Zurück zum Zitat Churpek JE (2016) Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies, Blood Churpek JE (2016) Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies, Blood
10.
Zurück zum Zitat Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27(3):263–270CrossRefPubMed Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27(3):263–270CrossRefPubMed
11.
Zurück zum Zitat Li R, Sobreira N, Witmer PD, Pratz KW, Braunstein EM (2016) Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. Haematologica 101(6):e228–e231CrossRefPubMedPubMedCentral Li R, Sobreira N, Witmer PD, Pratz KW, Braunstein EM (2016) Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. Haematologica 101(6):e228–e231CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Cardoso SR, Ryan G, Walne AJ, Ellison A, Lowe R, Tummala H et al (2016) Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia 30(10):2083–2086CrossRefPubMedPubMedCentral Cardoso SR, Ryan G, Walne AJ, Ellison A, Lowe R, Tummala H et al (2016) Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia 30(10):2083–2086CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351(23):2403–2407CrossRefPubMed Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351(23):2403–2407CrossRefPubMed
14.
Zurück zum Zitat Dickinson RE, Griffin H, Bigley V, Reynard LN, Hussain R, Haniffa M et al (2011) Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 118(10):2656–2658CrossRefPubMedPubMedCentral Dickinson RE, Griffin H, Bigley V, Reynard LN, Hussain R, Haniffa M et al (2011) Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 118(10):2656–2658CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY et al (2011) Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118(10):2653–2655CrossRefPubMedPubMedCentral Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY et al (2011) Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118(10):2653–2655CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al (1999) Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23(2):166–175CrossRefPubMed Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al (1999) Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23(2):166–175CrossRefPubMed
18.
Zurück zum Zitat Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR et al (2015) Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 47(2):180–185CrossRefPubMedPubMedCentral Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR et al (2015) Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 47(2):180–185CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Haslam K, Langabeer SE, Hayat A, Conneally E, Vandenberghe E (2016) Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. Br J Haematol 175(1):161–163CrossRefPubMed Haslam K, Langabeer SE, Hayat A, Conneally E, Vandenberghe E (2016) Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. Br J Haematol 175(1):161–163CrossRefPubMed
20.
Zurück zum Zitat Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N et al (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113(22):5583–5587CrossRefPubMed Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N et al (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113(22):5583–5587CrossRefPubMed
21.
Zurück zum Zitat Ding LW, Ikezoe T, Tan KT, Mori M, Mayakonda A, Chien W, et al. (2016) Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency. Leukemia Ding LW, Ikezoe T, Tan KT, Mori M, Mayakonda A, Chien W, et al. (2016) Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency. Leukemia
22.
Zurück zum Zitat Godley LA (2014) Inherited predisposition to acute myeloid leukemia. Semin Hematol 51(4):306–321CrossRefPubMed Godley LA (2014) Inherited predisposition to acute myeloid leukemia. Semin Hematol 51(4):306–321CrossRefPubMed
23.
Zurück zum Zitat DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M et al (2016) Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC). Clin Lymphoma, Myeloma Leuk 16(7):417–28.e2CrossRef DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M et al (2016) Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC). Clin Lymphoma, Myeloma Leuk 16(7):417–28.e2CrossRef
24.
Zurück zum Zitat Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A et al (2015) Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet 47(5):535–538CrossRefPubMedPubMedCentral Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A et al (2015) Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet 47(5):535–538CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Vulliamy T, Marrone A, Dokal I, Mason PJ (2002) Association between aplastic anaemia and mutations in telomerase RNA. Lancet 359(9324):2168–2170CrossRefPubMed Vulliamy T, Marrone A, Dokal I, Mason PJ (2002) Association between aplastic anaemia and mutations in telomerase RNA. Lancet 359(9324):2168–2170CrossRefPubMed
26.
Zurück zum Zitat Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ et al (2005) Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352(14):1413–1424CrossRefPubMed Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ et al (2005) Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352(14):1413–1424CrossRefPubMed
27.
Zurück zum Zitat Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447CrossRefPubMedPubMedCentral Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Churpek JE, Lorenz R, Nedumgottil S, Onel K, Olopade OI, Sorrell A et al (2013) Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma 54(1):28–35CrossRefPubMed Churpek JE, Lorenz R, Nedumgottil S, Onel K, Olopade OI, Sorrell A et al (2013) Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma 54(1):28–35CrossRefPubMed
29.
Zurück zum Zitat Green CL, Tawana K, Hills RK, Bodor C, Fitzgibbon J, Inglott S et al (2013) GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol 161(5):701–705CrossRefPubMed Green CL, Tawana K, Hills RK, Bodor C, Fitzgibbon J, Inglott S et al (2013) GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol 161(5):701–705CrossRefPubMed
30.
Zurück zum Zitat Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B et al (2012) GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 120(2):395–403CrossRefPubMed Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B et al (2012) GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 120(2):395–403CrossRefPubMed
31.
Zurück zum Zitat Osato M, Yanagida M, Shigesada K, Ito Y (2001) Point mutations of the RUNx1/AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 74(3):245–251CrossRefPubMed Osato M, Yanagida M, Shigesada K, Ito Y (2001) Point mutations of the RUNx1/AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 74(3):245–251CrossRefPubMed
32.
Zurück zum Zitat Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the acute leukemia French association (ALFA). Blood 100(8):2717–2723CrossRefPubMed Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the acute leukemia French association (ALFA). Blood 100(8):2717–2723CrossRefPubMed
33.
Zurück zum Zitat Galili NT, Trifonov, V., Ewalt, M., Mukherjee, S., Rabadan, R., Raza, A. (2012) Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) Blood. 120:169 Galili NT, Trifonov, V., Ewalt, M., Mukherjee, S., Rabadan, R., Raza, A. (2012) Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) Blood. 120:169
34.
Zurück zum Zitat Yang F, Gong Q, Shi W, Zou Y, Shi J, Wei F et al (2016) Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation. Tumour Biol 37(9):12609–12618CrossRefPubMed Yang F, Gong Q, Shi W, Zou Y, Shi J, Wei F et al (2016) Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation. Tumour Biol 37(9):12609–12618CrossRefPubMed
Metadaten
Titel
Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary
verfasst von
Attila Péter Király
Krisztián Kállay
Ambrus Gángó
Ádám Kellner
Miklós Egyed
Anita Szőke
Richárd Kiss
István Vályi-Nagy
Judit Csomor
András Matolcsy
Csaba Bödör
Publikationsdatum
29.03.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0216-4

Weitere Artikel der Ausgabe 1/2018

Pathology & Oncology Research 1/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.